Bausch Investors Initially Pessimistic Following B+L Spinout
Bausch Health Drops 27% Following Q1 Earnings Call
With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.
You may also be interested in...
Bausch + Lomb Turns To Familiar Face As CEO, Brent Saunders
Saunders will oversee the consumer health, pharma and medtech eye health and vision care specialist, returning to where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.
Bausch + Lomb Taps A Familiar Face, Brent Saunders, As Next CEO
Saunders will oversee the eye specialist, returning to the firm where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.
Bausch + Lomb Micronizes Lutein, Zeaxanthin In PreserVision OCUSorb
PreserVision AREDS 2 mini-softgel has proprietary OCUSorb formulation with micronized ingredients in a medium-chain triglyceride oil. More than line extensions, though, are needed for B+L to shed influence from Bausch Health’s credit rating.